Why hormone therapy is still underused, 24 years after the WHI

In July 2002, the Women’s Health Initiative estrogen-plus-progestin arm was stopped early and announced at a press conference before most clinicians had read the paper. Hormone therapy use fell by more than half within a few years and never fully recovered. Two decades later, the fear it created is still one of the main reasons the most effective treatment for menopausal symptoms is underprescribed — and one of the main reasons an unregulated market grew in its place.

What the trial actually studied

• The average participant was 63 years old — more than a decade past the typical age of symptom onset. Only a minority were in their fifties.
• It tested one regimen: oral conjugated equine estrogens with medroxyprogesterone acetate. It did not test transdermal estradiol with micronized progesterone, the combination most commonly prescribed today.
• It was designed as a chronic disease prevention trial, not a symptom treatment trial. Women with significant vasomotor symptoms were largely excluded.

What the numbers meant

The widely quoted "26% increase in breast cancer risk" was a relative risk. In absolute terms it corresponded to roughly 8 additional cases per 10,000 women per year in the combined-therapy arm, and it did not reach statistical significance in the original report. The estrogen-alone arm — women who had had a hysterectomy — showed no increase in breast cancer incidence, and in longer follow-up showed a reduction. Almost none of that nuance reached the public.

What later analysis established

• Timing matters. In women who begin hormone therapy under 60, or within 10 years of their final period, the benefit-risk balance is generally favourable — the "window of opportunity."
• Route matters. Transdermal estradiol avoids hepatic first pass and carries a lower venous thromboembolism risk than oral estrogen.
• Progestogen choice matters. Micronized progesterone has a different risk profile from medroxyprogesterone acetate.
• Vaginal estrogen is a separate question. Low-dose local therapy for genitourinary syndrome of menopause has minimal systemic absorption and is appropriate for the large majority of women, including many with a breast cancer history after specialist discussion.

Why the correction never landed

Guidelines were slow to be rewritten and slower to reach practice. A generation of clinicians trained during the post-2002 collapse learned hormone therapy as a liability rather than a tool. Menopause education stayed thin in residency. And the loudest voices correcting the record were often on social media rather than in clinics — which restored enthusiasm without restoring rigour, and opened the door to overprescribing, pellets, and hormone-panel-driven dosing at the other extreme.

Where guidance stands in 2026

The Menopause Society’s 2022 position statement supports hormone therapy as first-line treatment for moderate-to-severe vasomotor symptoms and for prevention of bone loss in women under 60 or within 10 years of menopause onset, absent contraindications. It is not recommended for primary prevention of cardiovascular disease or dementia — a claim that appears constantly in wellness marketing and that we refuse to make. Contraindications still matter: active or recent breast cancer, prior VTE or stroke, and unexplained vaginal bleeding all require specialist evaluation, which is what our complex-care pathway exists for.

The practical takeaway is unglamorous. Hormone therapy is neither the danger the 2002 headlines implied nor the panacea your feed suggests. It is a well-characterised treatment that works well for a defined population, with dose, route, and timing that should be chosen deliberately. Our [compounded HRT policy](/compounded-hrt-policy) and [clinical governance standards](/clinical-governance) set out how we make those calls.

Medically reviewed by Kindr Health Clinical Team
Kindr Health Inc. — Editorial & Clinical Team (physician-supervised)
NPI 1609792902 · Last reviewed: July 3, 2026